TrialWorld journal of urology2005

Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder.

Norman Zinner et al.PubMed ↗Publisher ↗

No numbers read from the abstract.